Glioblastoma trial design is expanding and becoming more suited to clinical practice

Researchers at the University of Tsukuba have investigated the changes in the primary evaluation items in phase II clinical trials for glioblastoma, a type of brain tumor. Recently, the items have become more diverse, with more time-to-event indicators such as survival time being used, whereas the use of response rate, which indicates the proportion of patients whose cancer has shrunk, has decreased. These changes indicate that the design of trials is becoming more comprehensive and more adapted to clinical practice.

👉 Full Story